Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Purple Biotech ( (PPBT) ) has issued an update.
On January 12, 2026, Purple Biotech released an updated corporate presentation outlining progress on its CAPTN‑3 tri‑specific antibody platform and near‑term milestones for its oncology pipeline. The company highlighted lead candidate IM1240, a capped CD3x5T4xNKG2A antibody for solid tumors that showed a 300‑fold safety margin versus its non‑capped variant in preclinical models and is slated for GLP toxicology completion, IND submission, and Phase 1 initiation in the second half of 2026. The presentation also positioned Phase 2 assets CM24 (pancreatic cancer) and NT219 (head and neck cancer) as partnership opportunities, with interim Phase 2 data for NT219 expected in 2026 and a Phase 2b start for CM24 contingent on partnering, framing 2026 as a catalyst‑rich year that could de‑risk the CAPTN‑3 platform and potentially enhance Purple Biotech’s standing in the competitive immuno‑oncology space.
The most recent analyst rating on (PPBT) stock is a Hold with a $0.66 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Neutral.
The score is held down primarily by the lack of revenue, ongoing losses, and negative free cash flow, indicating continued reliance on external funding. Technical indicators also point to a bearish trend with weak momentum. The main positive is the low-debt balance sheet, which reduces near-term leverage risk but does not offset weak operating fundamentals.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical‑stage immuno‑oncology company listed on Nasdaq and the Tel Aviv Stock Exchange, focused on developing next‑generation multi‑specific antibody therapies for cancer. Its pipeline includes the CAPTN‑3 platform of conditionally activated tri‑specific antibodies that engage both T cells and NK cells against solid tumors, alongside clinical‑stage assets CM24 for pancreatic cancer and NT219 for head and neck cancer, with a reported cash position of $10.5 million as of September 30, 2025 and funding runway into the first half of 2027.
Average Trading Volume: 7,377,037
Technical Sentiment Signal: Sell
Current Market Cap: $7.11M
Learn more about PPBT stock on TipRanks’ Stock Analysis page.